Innovative New ASTRUM Product Officially Approved for Sale in Norway
STENOCARE Celebrates Denmark’s Permanent Legalisation of Medical Cannabis
Today, the Danish parliament formally agreed on permanent legalisation of medical cannabis. This is fantastic news for both Danish patients and Stenocare, as it ensures continued access to and the sale of medical cannabis in Denmark.
The political parties also agreed to enhance information and guidance for both doctors and patients. This includes providing treatment guidelines for doctors and permitting patients to continue driving while undergoing treatment with medical cannabis.
STENOCARE is Shortlisted for European Cannabis Company of the Year
Stenocare is honored to be recognized as one of the leading European Cannabis Companies in the industry annual award. 
STENOCARE launch next generation medical cannabis oil product in Australia – six months ahead of schedule
Stenocare´s new innovative product-line is ready for the market – six months ahead of expectation. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthrough allows for higher uptake in the blood, and reduced dosage requirements. The first Astrum product will be launched for patients in Australia during Summer 2024.
Major milestone reached: STENOCARE receives approval to sell a new medical cannabis oil product in Denmark
Stenocare has received approval from The Danish Medicines Agency to sell a new THC/CBD medical cannabis oil product to Danish patients. With this, Stenocare has regained the position as the exclusive (only) provider of all three essential oil products under the Danish Pilot Programme; THC oil, CBD oil, and now also the new THC/CBD oil.
Analyst Group provides comments on STENOCARE's expansion in Australia
For the full article on Analyst Group, click here.
Listen to Stenocare CEO present the company and industri insights
Stenocare’s CEO is featured in Aktieportföljen in Sweden, presenting the company and providing industry insights to investors.
BREAKING NEWS: Stenocare enter German market
Stenocare product approved by German health authorities, and are now entering Germany, which is our sixth country and the largest European market for medical cannabis!
Finwire interview with Stenocare CEO Thomas Skovlund Schnegelsberg
Finwire visited Stenocare in Copenhagen and met with CEO Thomas Skovlund Schnegelsberg. Hear about the cannabis market, business model, financial position, capital raising and why investors should take a closer look at Stenocare.
Strong platform that will carry us forward into 2023 and beyond
Join Thomas Skovlund Schnegelsberg, CEO of Stenocare, as he shares the exciting highlights from our just-released Annual Report 2022
STENOCARE enter Norway and now exclusively cover all Scandinavian countries.
STENOCARE approved to supply Danish patients with new CBD medical cannabis oil product
Stenocare has received approval from The Danish Medicines Agency to sell a new CBD medical cannabis oil product to Danish patients. With this, STENOCARE once again becomes the only supplier of both CBD and THC medical cannabis oil products under the Danish Pilot Programme. The product is called “CBD Olie STENOCARE” and contains 20 mg/mL CBD.
STENOCARE enters its 4th market starting sales in Australia in Q4 2022
Rolf Steno, Stenocare CCO and Rob Jenny, Cannvalate Business Development Manager closing the partnership agreement in Brisbane Australia. Stenocare enter the Australian market with the new oil product CBD-THC 12.5:12.5 Balanced (THC 12.5mg/mL + CBD 12.5mg/mL) that will be available to patients during Q4 2022 with sales expected to accelerate in the first half of 2023 and onwards.
Strong start for 2022 with new products in Denmark and the UK
Stenocare CEO, Thomas Skovlund Schnegelsberg, comments on the important Q1 milestones and key figures in the Q1 Report.
Stenocare initiates guidance: 15-20mDKK in annual revenue run rate by end of 2022
Stenocare has successfully reached two important license milestones during Q1 2022: This enables the company to realize sales to patients in Denmark, Sweden and the UK this year, with a gradual build-up of sales during the year. By the end of the year the expected sales run rate (calculated as Q4 times 4) is set at 15 to 20 million DKK.
Stenocare enters the UK market to sell prescription-based medical cannabis oil products
Stenocare to make medical cannabis oil products available for UK patients. With this Stenocare is taking a major step towards its goal of becoming a European market leader. Stenocare has been working extensively with their partners to establish the logistical setup to cover England, Scotland, Wales and Northern Ireland.
Stenocare approved to supply Danish patients with medical cannabis oil products
Stenocare received approval for a new product from The Danish Medicines Agency, and is again the first and only supplier of medical cannabis oil products for the Pilot Programme. The product is named “THC Olie STENOCARE” and contain 30 mg/mL THC and <0.1 mg/mL CBD, and comes in a 30 mL bottle with an oral syringe.
Healthy Focus On Profitable Business Models
Stenocare CEO Thomas Skovlund Schnegelsberg reflects on 2021 and looks ahead to the challenges and opportunities that lie ahead in 2022.
Click here for full article
Grow-technician is evaluating
The Stenocare grow-technician is evaluating the flower distribution and maturation stage during his inspection. The flower buds are bulking up with plant’s nutrients. The grower is closely monitoring the distribution of the flower buds and leaves for each individual plant. The plants are only few weeks away from harvest, and plant trimming is now concentrated on creating optimal light conditions for all flower buds.
Business perspective for Danish cultivation facility
Stenocare now has capacity to cover its expected supply needs for the next 4-5 years, corresponding to potential annual commercial value of DKK 150 mill from the Danish facility alone. This is not a forecast or guidance for 2022 or 2023, but provide a perspective of the potential capabilities of the Danish facility.
Guided tour in the flower room
Delivering safe prescription-based products to patients require maximum control of quality and documentation.
Guided tour in the water treatment area
Guided tour in the indoor facility area
Good news for the Danish medical cannabis patients and for the industry
Stenocare applauds the Danish Parliament decision to a) extend the Pilot Programme that allow Danish doctors to prescribe medical cannabis and b) to permanently allow local cultivation and production of medical cannabis. This is very good news for patients and the industry.
Prescription: The Danish Parliament today made the decision to extend the Pilot Programme for prescription of medical cannabis with another four years, when the current Pilot expires on 31th of December 2021. This will allow all doctors to continue prescribing medical cannabis products to their patients regardless of illness (ie. indication). The agreement also outlines, that Parliament will debate the levels of patient cost coverage or refund during the Autumn assembly.
Cultivation: The decision today also makes Danish cultivation and production of medical cannabis permanent beyond the expiration of the current Pilot in December 2021. With this decision, Denmark formally continues its ambition to become a leading producer of medical cannabis with an intention to serve both the home market and international markets.
Thomas Skovlund Schnegelsberg, CEO of Stenocare is commenting:
“Today is an important milestone for Danish patients and for the Danish medical cannabis industry. The Danish Parliament has decided to continue the Pilot Programme for patient’s treatment with high quality medical cannabis until 2025, and at the same time made the law for Danish cultivation and production permanent. With this decision, Denmark is now on a path to become a leading producer of medical cannabis for patients in Europa and be an important part of the hyper-growth expected in the coming years.”
Click here for link to The Danish Ministry of Health
Interview Q1 Report 2021
Helge Larsen from Proinvestor.com is interviewing Stenocare CEO about the Q1 2021 Report and state of the business (Danish interview with Swedish subtitles)
Thomas Skovlund Schnegelsberg participated in an interview with Invest Talks published on Dagens Industri (in Swedish)
You can read the full article here – Click here for PDF (PDF doc)
”2020 has both been a exiting and busy year for Stenocare” Stenocare CEO, Thomas Skovlund Schnegelsberg, look back at 2020
“2020 has been a highly extraordinary, yet also busy year for Stenocare. Therefore, I find it natural to share a few reflections as we are nearing the end of 2020. We entered the year with a clear focus upon our Stenocare 2.0 Strategy: to become a European leader within prescription-based medical cannabis”.
Click here for PDF
(PDF doc)
Times Square New York
The iconic “tower photo” from Times Square in New York.
Nasdaq First North Denmark welcomes Stenocare for the first day of trade.
Stenocare and NASDAQ sign the wall poster for the wall of fame
Ceremony of signing the wall poster.
Stenocare´s CEO Thomas Skovlund Schnegelsberg (left) and Carsten Borring (right), Head of Listings, Nasdaq Copenhagen.
Profitable Year-End Report
Join the CEO of Stenocare in his comments on the profitable Year-End Report 2019 and his reflections for the future growth of the company.
Stenocare is a ”company to watch” for 2020
The new edition of The European Cannabis Report 5th Edition was published February 2020, and in the section “Companies to Watch” the Report profile Stenocare as one of few medical cannabis leaders in Europe:
Quote from the Report:
“The company is now a leader in the European market; its production and distribution network in Denmark was profitable in 2018 and is currently expanding to Ireland among other emerging markets. This is notable as even large companies have struggled to produce a profit in the early years of the industry”
The European Cannabis Report is a comprehensive source of information covering each European country and its status/progress with medical cannabis. Therefore the Report offer a good insight into market opportunities, key stakeholders and how medical cannabis is applied for treatment of patients in Europe. The European Cannabis Report is free and is published by Prohibition Partners. Access the Report here.
Stenocare interview
Thomas Skovlund Schnegelsberg, CEO of Stenocare A/S present the Interim Report Second Quarter 2019 and inform about the current challenges relating to Stenocare’s Canadian partner, CannTrust. Annabella Pultz from Finwire is hosting the event.
Stenocare celebrated as the Best IPO 2018 at the ceremony hosted by SvD Börsplus.
The Stenocare Executive Management team, ring the bell at Spotlight Stock Market to start first trade of Stenocare stocks.
